DARPA's Potential Treatment for COVID-19

Stop Gap Covid-19 Treatment

Source:  DARPA

Race to Stop COVID-19 in its Tracks

The US Defense Department's Advanced

Research Projects Agency - DARPA -

has been given the green light to

fast track "mission critical" programs

to fight and defeat the coronavirus, 

which has infected nearly 1 million

Americans.  DARPA is a global

epicenter of breakthrough innovation.

It has created the internet, Artificial

Intelligence, cloud computing and 

much more.

Unique Stop Gap Therapy in the Pipeline

Right now, DARPA is working on a

therapy - what they're calling a

"firewall" - that would temporarily 

protect someone from contracting the

disease.  It is a stop-gap therapy

for use before a vaccine is created,

which is expected sometime in 2021 at

the earliest.

Firewall P3 Platform

DARPA wants their P3 Platform therapy 

to work immediately in the patient and last

for six months.  DARPA has identified

antibodies in people who overcame the

disease and they're turning that into 

the stop-gap therapy. They're taking the

genetic materials that code for those

antibodies and injecting them into

patients so their cells can make the 

antibodies. The procedure has already

been successful in limited human

trials.

Targeting Availability in 60 Days

DARPA's stop-gap therapy is

new, cutting edge, experimental

and real.  DARPA's track-record

of record-breaking global innovations

is unparalleled. It could be a light

at the end of the pandemic tunnel.

DARPA hopes to make

this potentially life saving therapy

available in 60 to 90 days.